Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica

Rhea-AI Summary

Nutriband (NASDAQ: NTRB) signed an exclusive distribution agreement with Costa Rica-based Innomedica for AVERSA fentanyl (upon approval) and all sports tape products manufactured at its Pocono Pharmaceutical / Active Intell subsidiary.

Innomedica will manage and finance regulatory approvals as products ramp up for launch in Costa Rica.

Positive

• Exclusive distribution agreement secured for Costa Rica market
• Innomedica to finance regulatory approvals for product launches
• Agreement covers AVERSA fentanyl upon approval and all sports tape products
• Includes products from Pocono Pharmaceutical / Active Intell subsidiary

Negative

• AVERSA fentanyl availability is contingent on regulatory approval
• Commercial reach initially limited to Costa Rica
• Dependence on a single distributor for market entry

ORLANDO, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products manufactured at its Pocono Pharmaceutical / Active Intell subsidiary. Innomedica will also be overseeing and financing all regulatory approvals for the above mentioned products as they ramp up for launch.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

SOURCE: Nutriband Inc.

FAQ

What did Nutriband (NTRB) announce on February 17, 2026 regarding distribution in Costa Rica?

Nutriband announced an exclusive distribution agreement with Innomedica for Costa Rica. According to the company, the deal covers AVERSA fentanyl upon approval and all sports tape products from its Pocono Pharmaceutical / Active Intell subsidiary.

Will Innomedica handle regulatory approvals for NTRB products in Costa Rica?

Yes. According to the company, Innomedica will oversee and finance all regulatory approvals. This financing applies as the products ramp up for launch, reducing Nutriband's immediate regulatory burden.

Does the Nutriband distribution deal include AVERSA fentanyl immediately for NTRB shareholders?

No — AVERSA fentanyl is included upon regulatory approval. According to the company, the agreement becomes effective for AVERSA only after required approvals are secured in Costa Rica.

Which Nutriband products are covered by the exclusive agreement with Innomedica?

The agreement covers AVERSA fentanyl (upon approval) and all sports tape products. According to the company, it also includes products manufactured at its Pocono Pharmaceutical / Active Intell subsidiary.

How might the Innomedica deal affect Nutriband's market entry timeline for NTRB products?

The deal could accelerate Costa Rica market entry because Innomedica will fund approvals. According to the company, Innomedica will manage regulatory steps as products ramp up for launch, potentially speeding commercialization.

Is the Nutriband distribution agreement for Costa Rica exclusive and what does that mean for NTRB?

Yes, the agreement is exclusive for Costa Rica. According to the company, exclusivity grants Innomedica sole distribution rights in Costa Rica for the specified products, centralizing market access and responsibilities.